Published in Nat Rev Mol Cell Biol on April 01, 2007
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov (2009) 10.32
Modes of p53 regulation. Cell (2009) 9.31
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell (2008) 6.93
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
p53 and metabolism. Nat Rev Cancer (2009) 5.05
Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature (2010) 5.02
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet (2008) 4.02
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol (2010) 3.77
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res (2008) 3.58
Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol (2014) 3.38
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J (2011) 3.06
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol (2008) 2.81
Cellular stress responses: cell survival and cell death. Int J Cell Biol (2010) 2.74
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Nucleolus, ribosomes, and cancer. Am J Pathol (2008) 2.53
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell (2010) 2.40
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol (2009) 2.35
Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J (2009) 2.31
Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2008) 2.21
Cellular senescence and tumor suppressor gene p16. Int J Cancer (2011) 2.14
The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol (2011) 2.13
Whole chromosome instability and cancer: a complex relationship. Trends Genet (2008) 2.04
Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A (2009) 2.00
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat (2009) 1.97
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A (2009) 1.94
p53 at a glance. J Cell Sci (2010) 1.88
p53: The Janus of autophagy? Nat Cell Biol (2008) 1.86
High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell (2013) 1.86
Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes (2008) 1.85
Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer (2011) 1.84
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2009) 1.79
The isoforms of the p53 protein. Cold Spring Harb Perspect Biol (2010) 1.76
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol (2007) 1.70
Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression. Mol Cell (2013) 1.67
The E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis. Dev Biol (2011) 1.67
Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol (2009) 1.66
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
Stressin' Sestrins take an aging fight. EMBO Mol Med (2010) 1.65
Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci U S A (2011) 1.65
Myc-driven endogenous cell competition in the early mammalian embryo. Nature (2013) 1.64
Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ (2011) 1.63
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
p53 and its isoforms in cancer. Br J Cancer (2007) 1.62
Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA (2009) 1.60
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res (2008) 1.58
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer (2011) 1.54
Cell fate decision mediated by p53 pulses. Proc Natl Acad Sci U S A (2009) 1.53
p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle (2010) 1.51
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ (2013) 1.50
Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev (2010) 1.50
S-glutathionylation: from molecular mechanisms to health outcomes. Antioxid Redox Signal (2011) 1.49
Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A (2009) 1.46
The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene (2009) 1.45
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
Alzheimer disease and cancer risk: a meta-analysis. J Cancer Res Clin Oncol (2014) 1.44
Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev (2012) 1.44
Telomeres and disease. EMBO J (2009) 1.41
Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A (2007) 1.41
ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell (2012) 1.40
MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A (2011) 1.39
Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev (2007) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry (2009) 1.35
Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol (2015) 1.33
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev (2014) 1.30
p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner. Proc Natl Acad Sci U S A (2015) 1.30
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl (2011) 1.30
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A (2010) 1.29
p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol (2008) 1.29
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res (2011) 1.29
Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther (2011) 1.29
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One (2009) 1.29
Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid Redox Signal (2011) 1.29
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife (2015) 1.28
Human hepatocyte carcinogenesis (review). Int J Oncol (2013) 1.28
The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med (2011) 1.28
Tubular p53 regulates multiple genes to mediate AKI. J Am Soc Nephrol (2014) 1.26
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem (2012) 1.26
International network of cancer genome projects. Nature (2010) 20.35
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell (2004) 4.46
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
The role of mutant p53 in human cancer. J Pathol (2010) 2.49
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J (2005) 2.12
Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer (2004) 2.10
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene (2002) 1.91
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer (2002) 1.84
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (2009) 1.64
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Ubiquitination of HEXIM1 by HDM2. Cell Cycle (2009) 1.46
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem (2008) 1.43
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem (2010) 1.32
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov (2008) 1.30
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res (2011) 1.29
Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle (2007) 1.28
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep (2008) 1.25
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle (2007) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc (2008) 1.16
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol (2012) 1.14
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci (2004) 1.13
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res (2005) 1.11
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett (2002) 1.10
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (2003) 1.09
Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle (2010) 1.09
p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. J Biol Chem (2004) 1.07
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer (2008) 1.06
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents (2003) 1.03
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther (2005) 1.03
Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett (2003) 1.03
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res (2007) 1.03
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep (2012) 1.03
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem (2009) 1.02
Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol (2008) 1.01
Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Cell Res (2013) 1.00
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol (2004) 0.99
Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α. J Virol (2012) 0.98
Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. BMC Bioinformatics (2009) 0.97
Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle (2007) 0.97
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 0.96
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle (2012) 0.96
Pilot screening programme for small molecule activators of p53. Int J Cancer (2005) 0.95
The p53 isoforms are differentially modified by Mdm2. Cell Cycle (2012) 0.94
Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc Natl Acad Sci U S A (2012) 0.93
Exploiting the p53 pathway for cancer diagnosis and therapy. Hematol J (2003) 0.91
Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL. Cell Cycle (2009) 0.91
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther (2004) 0.91
Oligomerization of the human ARF tumor suppressor and its response to oxidative stress. J Biol Chem (2003) 0.91
Modulating the p53 pathway. Semin Cancer Biol (2010) 0.90
The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle (2007) 0.90
Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. J Mol Biol (2007) 0.90
Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site. Cell Cycle (2009) 0.90
MDM4 downregulates p53 transcriptional activity and response to stress during differentiation. Cell Cycle (2011) 0.89
Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging. J Clin Invest (2014) 0.89
Turning the key on p53. Nature (2004) 0.87
Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle (2011) 0.87
Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding. Cell Cycle (2012) 0.87
The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. Mini Rev Med Chem (2003) 0.87
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer (2009) 0.87
Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. Cancer Res (2006) 0.86
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle (2008) 0.85
p53 transcriptional pathways in breast cancer: the good, the bad and the complex. J Pathol (2010) 0.84
Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics. PLoS One (2013) 0.84
NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds. Cell Cycle (2011) 0.84
Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations. PLoS One (2012) 0.83
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle (2013) 0.83
Investigating peptide sequence variations for 'double-click' stapled p53 peptides. Org Biomol Chem (2014) 0.83
Dimerization of the core domain of the p53 family: a computational study. Cell Cycle (2009) 0.83
Differences in the transactivation domains of p53 family members: a computational study. BMC Genomics (2010) 0.83
The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4. J Biomol Screen (2014) 0.82
Detecting p53 isoforms at protein level. Methods Mol Biol (2013) 0.81
Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Methods Mol Biol (2013) 0.81
Scotin: A new p63 target gene expressed during epidermal differentiation. Biochem Biophys Res Commun (2007) 0.81
Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting. J Mol Biol (2009) 0.80
Regulation of the p14ARF promoter by DNA methylation. Cell Cycle (2007) 0.80
Substrate specificity of cyclins determined by electrostatics. Cell Cycle (2007) 0.79
A comparison and optimization of methods and factors affecting the transformation of Escherichia coli. Biosci Rep (2013) 0.79
SNPing Away at Cancer. Cancer Cell (2010) 0.78
Detection of the 113p53 protein isoform: a p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish. Cell Cycle (2010) 0.78
Seeking synergy in p53 transcriptional activation for cancer therapy. Discov Med (2012) 0.78
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl. Bioorg Med Chem Lett (2008) 0.78